DOCSLIB.ORG

Report of the Scientific Committee on Food on the Revision of Essential Requirements of Infant Formulae and Follow-On Formulae

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Report of the Scientific Committee on Food on the Revision of Essential Requirements of Infant Formulae and Follow-On Formulae EUROPEAN COMMISSION HEALTH and CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Scientific Opinions C2 - Management of scientific committees; scientific co-operation and networks Scientific Committee on Food SCF/CS/NUT/IF/65 Final 18 May 2003 Report of the Scientific Committee on Food on the Revision of Essential Requirements of Infant Formulae and Follow-on Formulae (adopted on 4 April 2003) Contains a corrigendum made on 17/09/2007 on page 60, chapter 4.7.2 Carnitine B-1049 Bruxelles/ Brussels - Belgium Telephone: direct line (+32-2) 29 581.10/659.48/648.70, exchange 299.11.11. Fax: (+32-2) 299.48.91 Telex: COMEU B 21877. Telegraphic address: COMEUR Brussels. http://europa.eu.int/comm/food/fs/sc/scf/index_en.html TABLE OF CONTENTS LIST OF ABBREVIATIONS................................................................................................ 10 TERMS OF REFERENCE AND BACKGROUND ........................................................... 12 Terms of Reference ................................................................................................................ 12 Background............................................................................................................................. 12 Acknowledgements................................................................................................................. 12 I. INTRODUCTION AND GENERAL ASPECTS..................................................... 13 1. General aspects of infant feeding .................................................................. 13 2. Breast-feeding ................................................................................................. 13 3. Infant formulae and follow-on formulae ...................................................... 14 4. General principles adopted in the Committee’s scientific review on requirements of infant formulae and follow-on formulae .......................... 14 II. ENERGY CONTENT ................................................................................................ 17 1. Current requirements concerning minimum and maximum energy content in infant formulae and follow-on formulae marketed in the EU ............... 17 2. Comments on the existing requirements concerning energy in infant formulae and follow-on formulae in the Infant Formulae Directive ......... 17 2.1. Energy density of human milk.............................................................. 17 2.2. Growth of breast-fed and formula-fed infants ...................................... 17 2.3. Energy requirements of infants............................................................. 19 2.4. Energy expenditure: comparison between breast-fed and formula-fed infants.................................................................................................... 20 2.5. Feeding in early childhood and later growth, and nutritional status..... 22 3. Minimum and maximum energy content in infant formulae and follow-on formulae........................................................................................................... 22 4. Conclusion and recommendation.................................................................. 25 2 III. PROTEIN CONTENT ............................................................................................... 26 1. Introduction .................................................................................................... 26 2. General considerations on protein in formulae ........................................... 26 2.1. Protein composition of infant formulae and human milk..................... 26 2.2. Protein composition of follow-on formulae.......................................... 31 2.3. Effects of processing on nutritional value ............................................ 33 2.4. Recommendation .................................................................................. 34 3. Current requirements concerning protein in infant formulae and follow- on formulae in the Infant Formulae Directive............................................. 34 3.1. Calculation of protein ........................................................................... 34 3.2. Sources of protein ................................................................................. 34 3.3. Protein content ...................................................................................... 35 3.4. Protein quality....................................................................................... 35 3.5. Amino acid pattern of the reference proteins human milk and cows’ milk casein ............................................................................................ 36 4. Comments on the existing requirements for protein................................... 37 4.1. Calculation of protein content............................................................... 37 4.1.1. Calculation from nitrogen content ......................................................37 4.1.2. Protein determination..........................................................................38 4.1.3. Protein as sum of amino acids.............................................................39 4.1.4. Conclusion and recommendation........................................................40 4.2. Protein sources...................................................................................... 41 4.2.1. Proteins permitted ...............................................................................41 4.2.2. Other milks..........................................................................................41 4.2.2.1. Protein and amino acids...................................................................41 4.2.2.2. Digestibility .....................................................................................42 4.2.2.3. Allergenicity ....................................................................................42 4.2.2.4. Bioavailability of nutrients ..............................................................42 4.2.3. Plant proteins (vegetables and legumes)............................................ 42 4.2.3.1. Soy protein-based infant formulae...................................................42 4.2.3.2. Protein and amino acids, digestibility, bioavailability of nutrients, allergenicity of other plant proteins .................................................45 4.2.4. Recommendation ................................................................................45 4.3. Protein hydrolysates.............................................................................. 45 4.3.1. Conclusion and recommendation........................................................48 3 4.4. Protein content ...................................................................................... 48 4.4.1. The model of human milk...................................................................48 4.4.2. Protein requirements from studies with infant formulae compared to the human milk model ........................................................................48 4.4.3. The minimum protein content in infant formulae...............................50 4.4.4. The minimum protein content in follow-on formulae.........................51 4.4.5. The maximum protein content in infant formulae ..............................53 4.4.6. The maximum protein content in follow-on formulae........................53 4.5. Protein quality...................................................................................... .53 4.5.1. Amino acid score ................................................................................54 4.5.2. Protein Efficiency Ratio (PER) and Net Protein Utilisation (NPU) .. 54 4.5.3. Other qualifying factors for protein ....................................................54 4.6. Amino acids in reference proteins ........................................................ 55 4.6.1. Comparison to the FAO/WHO/UNU scoring pattern.........................55 4.6.2. Other scoring patterns.........................................................................56 4.6.3. Recommendation ................................................................................59 4.7. Taurine, carnitine, nucleotides, choline and other nitrogen-containing compounds............................................................................................ 59 4.7.1. Taurine ................................................................................................59 4.7.2. Carnitine..............................................................................................60 4.7.3. Nucleotides and nucleosides ...............................................................60 4.7.4. Choline................................................................................................64 4.7.5. Other nitrogen-containing compounds................................................65 5. Summary of all conclusions and recommendations .................................... 65 6. Recommendations for future work............................................................... 68 IV. FAT CONTENT ......................................................................................................... 69 1. Introduction .................................................................................................... 69 2. Total fat ........................................................................................................... 70 2.1. Structured triglycerides........................................................................
Load more

Recommended publications
  • Dysmagnesemia in Covid-19 Cohort Patients: Prevalence and Associated Factors
    Magnesium Research 2020; 33 (4): 114-122 ORIGINAL ARTICLE Dysmagnesemia in Covid-19 cohort patients: prevalence and associated factors Didier Quilliot1, Olivier Bonsack1, Roland Jaussaud2, Andre´ Mazur3 1 Transversal Nutrition Unit and; 2 Internal Medicine and Clinical Immunology. Nancy University Hospital, University of Lorraine, France; 3 Universite´ Clermont Auvergne, INRAE, UNH, Unite´ de Nutrition Humaine, Clermont-Ferrand, France Correspondence <[email protected]> Abstract. Hypomagnesemia and hypermagnesemia could have serious implications and possibly lead to progress from a mild form to a severe outcome of Covid-19. Susceptibility of subjects with low magnesium status to develop and enhance this infection is possible. There is little data on the magnesium status of patients with Covid-19 with different degrees of severity. This study was conducted to evaluate prevalence of dysmagnesemia in a prospective Covid-19 cohort study according to the severity of the clinical manifestations and to identify factors associated. Serum magnesium was measured in 300 of 549 patients admitted to the hospital due to severe Covid-19. According to the WHO guidelines, patients were classified as moderate, severe, or critical. 48% patients had a magnesemia below 0.75 mmol/L (defined as magnesium deficiency) including 13% with a marked hypomagnesemia (<0.65 mmol/L). 9.6% had values equal to or higher than 0.95 mmol/L. Serum magnesium concentrations were significantly lower in female than in male (0.73 Æ 0.12 vs 0.80 Æ 0.13 mmol/L), whereas the sex ratio M/F was higher in severe and critical form (p<0.001). In a bivariate analysis, the risk of magnesium deficiency was significantly and negatively associated with infection severity (p<0.001), sex ratio (M/F, p<0.001), oxygenotherapy (p<0.001), stay in critical care unit (p=0.028), and positively with nephropathy (p=0.026).
    [Show full text]
  • Michael Crichton and the Distancing of Scientific Discourse
    ASp la revue du GERAS 55 | 2009 Varia Apparent truth and false reality: Michael Crichton and the distancing of scientific discourse Stéphanie Genty Electronic version URL: http://journals.openedition.org/asp/290 DOI: 10.4000/asp.290 ISBN: 978-2-8218-0408-1 ISSN: 2108-6354 Publisher Groupe d'étude et de recherche en anglais de spécialité Printed version Date of publication: 1 March 2009 Number of pages: 95-106 ISSN: 1246-8185 Electronic reference Stéphanie Genty, « Apparent truth and false reality: Michael Crichton and the distancing of scientific discourse », ASp [Online], 55 | 2009, Online since 01 March 2012, connection on 02 November 2020. URL : http://journals.openedition.org/asp/290 ; DOI : https://doi.org/10.4000/asp.290 This text was automatically generated on 2 November 2020. Tous droits réservés Apparent truth and false reality: Michael Crichton and the distancing of scie... 1 Apparent truth and false reality: Michael Crichton and the distancing of scientific discourse Stéphanie Genty Introduction 1 This article began as an inquiry into the relation of FASP, or professional-based fiction, to professional reality. I was interested in elucidating the ways in which this reality, which formed the basis for such fiction, was transformed by the writer in his/her work and the reasons behind the transformation. Since my own professional activity has been related to the sciences, I chose to study the novels of Michael Crichton, a commercially-successful writer whose credentials and practice qualify him as an author of professional-based fiction as defined by Michel Petit in his 1999 article “La fiction à substrat professionnel: une autre voie d'accès à l'anglais de spécialité”.
    [Show full text]
  • Increased Mortality Associated with Hypermagnesemia in Severe COVID-19 Illness
    Original Investigation Increased Mortality Associated with Hypermagnesemia in Severe COVID-19 Illness Jacob S. Stevens 1,2, Andrew A. Moses1, Thomas L. Nickolas1,2, Syed Ali Husain1,2, and Sumit Mohan1,2,3 Key Points Hypermagnesemia is common in patients admitted with coronavirus disease 2019. The development of hypermagnesemia in coronavirus disease 2019 is associated with renal failure and markers of high cell turnover. In adjusted models, patients who develop hypermagnesemia have an increased risk of mortality. Abstract Background Although electrolyte abnormalities are common among patients with COVID-19, very little has been reported on magnesium homeostasis in these patients. Here we report the incidence of hypermagnesemia, and its association with outcomes among patients admitted with COVID-19. Methods We retrospectively identified all patients with a positive test result for SARS-CoV-2who were admitted to a large quaternary care center in New York City in spring 2020. Details of the patients’ demographics and hospital course were obtained retrospectively from medical records. Patients were defined as having hypermagnesemia if their median magnesium over the course of their hospitalization was .2.4 mg/dl. Results A total of 1685 patients hospitalized with COVID-19 had their magnesium levels checked during their hospitalization, and were included in the final study cohort, among whom 355 (21%) had hypermagnesemia. Patients who were hypermagnesemic had a higher incidence of shock requiring pressors (35% vs 27%, P,0.01), respiratory failure requiring mechanical ventilation (28% vs 21%, P50.01), AKI (65% vs 50%, P,0.001), and AKI severe enough to require renal replacement therapy (18% vs 5%, P,0.001).
    [Show full text]
  • Early-Onset Neonatal Hyperkalemia Associated with Maternal
    Tanaka et al. BMC Pediatrics (2018) 18:55 https://doi.org/10.1186/s12887-018-1048-4 CASEREPORT Open Access Early-onset neonatal hyperkalemia associated with maternal hypermagnesemia: a case report Kenichi Tanaka1, Hiroko Mori1, Rieko Sakamoto2, Shirou Matsumoto2, Hiroshi Mitsubuchi1, Kimitoshi Nakamura2 and Masanori Iwai1* Abstract Background: Neonatal nonoliguric hyperkalemia (NOHK) is a metabolic abnormality that occurs in extremely premature neonates at approximately 24 h after birth and is mainly due to the immature functioning of the sodium (Na+)/potassium (K+) pump. Magnesium sulfate is frequently used in obstetrical practice to prevent preterm labor and to treat preeclampsia; this medication can also cause hypermagnesemia and hyperkalemia by a mechanism that is different from that of NOHK. Herein, we report the first case of very early-onset neonatal hyperkalemia induced by maternal hypermagnesemia. Case presentation: A neonate born at 32 weeks of gestation developed hyperkalemia (K+ 6.4 mmol/L) 2 h after birth. The neonate’s blood potassium concentration reached 7.0 mmol/L 4 h after birth, despite good urine output. The neonate and his mother had severe hypermagnesemia caused by intravenous infusion of magnesium sulfate given for tocolysis due to pre-term labor. Conclusion: The early-onset hyperkalemia may have been caused by the accumulation of potassium ions transported through the placenta, the shift of potassium ions from the intracellular to the extracellular space in the infant due to the malfunctioning of the Na+/K+ pump and the inhibition of renal distal tube potassium ion secretion, there is a possibility that these mechanisms were induced by maternal and fetal hypermagnesemia after maternal magnesium sulfate administration.
    [Show full text]
  • Electrolyte Disorders and Arrhythmogenesis
    Cardiology Journal 2011, Vol. 18, No. 3, pp. 233–245 Copyright © 2011 Via Medica REVIEW ARTICLE ISSN 1897–5593 Electrolyte disorders and arrhythmogenesis Nabil El-Sherif1, Gioia Turitto2 1State University of NY, Downstate Medical Center and NY Harbor VA Healthcare System, Brooklyn, NY, USA 2Methodist University Hospital, Brooklyn, NY, USA Abstract Electrolyte disorders can alter cardiac ionic currents kinetics and depending on the changes can promote proarrhythmic or antiarrhythmic effects. The present report reviews the mecha- nisms, electrophysiolgical (EP), electrocardiographic (ECG), and clinical consequences of elec- trolyte disorders. Potassium (K+) is the most abundent intracellular cation and hypokalemia is the most commont electrolyte abnormality encountered in clinical practice. The most signifcant ECG manifestation of hypokalemia is a prominent U wave. Several cardiac and + non cardiac drugs are known to suppress the HERG K channel and hence the IK, and especially in the presence of hypokalemia, can result in prolonged action potential duration and QT interval, QTU alternans, early afterdepolarizations, and torsade de pointes ventricu- lar tachyarrythmia (TdP VT). Hyperkalemia affects up to 8% of hospitalized patients mainly in the setting of compromised renal function. The ECG manifestation of hyperkalemia de- pends on serum K+ level. At 5.5–7.0 mmol/L K+, tall peaked, narrow-based T waves are seen. At > 10.0 mmol/L K+, sinus arrest, marked intraventricular conduction delay, ventricular techycardia, and ventricular fibrillation can develop. Isolated abnormalities of extracellular calcium (Ca++) produce clinically significant EP effects only when they are extreme in either direction. Hypocalcemia, frequently seen in the setting of chronic renal insufficiency, results in prolonged ST segment and QT interval while hypercalcemia, usually seen with hyperparathy- roidism, results in shortening of both intervals.
    [Show full text]
  • Front Matter (PDF)
    HIGH RATE OF SUCCESS IN AN NIH- STUDY of hypertensive patients- highest percentage - remained on itial therapy 83% with NORVASC#{174}(amlodipi besylate) after 4 years; nearly all pati were on the 5-mg starting dose’ LOW RATE DISCONTINUATION ONLY 1.5%of patients in placebo studies (n= 1730) discontinued due to adverse effects2 PROVEN No negative inotropic effects clinical doses in hemodyna m ic stud 2* No clinically significant effect on cardiac conduction or heart rate2 *S1IflH,jr fiernodynamic findings, hcvever fiave been agents possessing significant neqafive notropic ebecto and 10-mg tablets Once-Daily NORV (ambdipine EFFICACY AND SAFETY THAT’S EASY TO WITH Br$e(Summary NORVASC(amlodlpine besylate) Tablets For Oral Use CONTRAINDICATIONS: NORVASC is contraindicated in patients with known sensitivity to arniodipirre. In hypertension WARNINGS: Increased Angina and/or MyOcardIal Infarction: Rarely, patients, particulady those with severe obstruc5ve coronary artery disease, have developed documented increased frequency,durationand/or severity of angina or acute myocardial infarction on starhng cafrium channel blocker therapy or attire time of dosage increase. The mechanism of this effect has not been elucidated. PRECAUTIONS: General: Since the vasoditation induced by NORVASC is gradual in onset, acute hypotension has rarely been reported after oraladministrationof NORVASC. Nonethetuss, caution should be exercised when admin- or angina, convenient istering NORVASC as with any other penpherio vasodilator particularly in pahentswithsevere
    [Show full text]
  • Ficta: Remixing Generalized Symbolic Media in the New Scientific Novel Brier, Søren
    www.ssoar.info Ficta: remixing generalized symbolic media in the new scientific novel Brier, Søren Postprint / Postprint Zeitschriftenartikel / journal article Zur Verfügung gestellt in Kooperation mit / provided in cooperation with: www.peerproject.eu Empfohlene Zitierung / Suggested Citation: Brier, S. (2006). Ficta: remixing generalized symbolic media in the new scientific novel. Public Understanding of Science, 15(2), 153-174. https://doi.org/10.1177/0963662506059441 Nutzungsbedingungen: Terms of use: Dieser Text wird unter dem "PEER Licence Agreement zur This document is made available under the "PEER Licence Verfügung" gestellt. Nähere Auskünfte zum PEER-Projekt finden Agreement ". For more Information regarding the PEER-project Sie hier: http://www.peerproject.eu Gewährt wird ein nicht see: http://www.peerproject.eu This document is solely intended exklusives, nicht übertragbares, persönliches und beschränktes for your personal, non-commercial use.All of the copies of Recht auf Nutzung dieses Dokuments. Dieses Dokument this documents must retain all copyright information and other ist ausschließlich für den persönlichen, nicht-kommerziellen information regarding legal protection. You are not allowed to alter Gebrauch bestimmt. Auf sämtlichen Kopien dieses Dokuments this document in any way, to copy it for public or commercial müssen alle Urheberrechtshinweise und sonstigen Hinweise purposes, to exhibit the document in public, to perform, distribute auf gesetzlichen Schutz beibehalten werden. Sie dürfen dieses or otherwise use the document in public. Dokument nicht in irgendeiner Weise abändern, noch dürfen By using this particular document, you accept the above-stated Sie dieses Dokument für öffentliche oder kommerzielle Zwecke conditions of use. vervielfältigen, öffentlich ausstellen, aufführen, vertreiben oder anderweitig nutzen. Mit der Verwendung dieses Dokuments erkennen Sie die Nutzungsbedingungen an.
    [Show full text]
  • Women'shealthreport
    Issue 4, 2014 Women’sHealthREPORT A QuaRTERLY PubLicatiON OF WOMEN’S HEALth diETEtic PRacticE GROup MICRONUTRIENTS AND THE OLDER ADULT – Part 1: Micronutrients of Importance to Older Adults By Vijaya Jain, MS, MSc, RD, CDN among older adults. A decreased energy intake associated with advancing age has important implications in terms of nutrient intake among older adults, including protein and micronutrients. Suboptimal intake for several micronutrients is prevalent among older adults. INTRODUCTION Increasing life expectancy has led to a steady rise in the number of older persons globally. In 2012, the number of older Americans aged 65 years and older had reached 43.1 million (1). As many of these older Americans continue to remain healthy and active well into their eighties and even nineties, and have better medi- cal management of chronic diseases and their comorbidities, the size of the older population is projected to double between 2000 and 2030 (2). According to the US Bureau of the Census, the size of the population age 85 and over is projected to be 7 Note from Chair: Collaboration is essential to the success of both million by 2020 (1). The baby-boomer generation will reach age individuals and organizations. It is has been a personal goal of mine 65 between 2010 and 2030, meaning that by 2030, one in five to see the Women’s Health DPG work with other DPGs and related American citizens will be older adults (1), and two out of every health organizations. In recent years, we have enhanced our mission three older Americans will have multiple chronic conditions (3).
    [Show full text]
  • Yeshiva University • Sukkot To-Go • Tishrei 5770
    1 YESHIVA UNIVERSITY • SUKKOT TO-GO • TISHREI 5770 Tishrei 5770 Dear Friends, may serve to enhance your ספר It is my sincere hope that the Torah found in this virtual .(study) לימוד holiday) and your) יום טוב We have designed this project not only for the individual, studying alone, but perhaps even a pair studying together) that wish to work through the study matter) חברותא more for a together, or a group engaged in facilitated study. להגדיל תורה ,With this material, we invite you to join our Beit Midrash, wherever you may be to enjoy the splendor of Torah) and to engage in discussing issues that touch on a) ולהאדירה most contemporary matter, and are rooted in the timeless arguments of our great sages from throughout the generations. Bivracha, Rabbi Kenneth Brander Dean, Yeshiva University Center for the Jewish Future Richard M Joel, President, Yeshiva University Rabbi Kenneth Brander, Dean, Center for the Jewish Future Rabbi Robert Shur, General Editor Copyright © 2009 All rights reserved by Yeshiva University Yeshiva University Center for the Jewish Future 500 West 185th Street, Suite 413, New York, NY 10033 [email protected] • 212.960.5400 x 5313 2 YESHIVA UNIVERSITY • SUKKOT TO-GO • TISHREI 5770 Table of Contents Sukkot 2009/5770 Koheleth: Looking Too Far Ahead Rabbi Norman Lamm. Page 4 Introduction to Kohelet: Sanctifying the Human Perspective Rabbi Hayyim Angel . Page 9 Halachic Issues Commonly Encountered During a Hotel Stay on Shabbat and Yom Tov Rabbi Joshua Flug . Page 18 Once Upon a Time: The Story Told by the Chagim Mrs. Dena Knoll .
    [Show full text]
  • Remixing Generalized Symbolic Media in the New Scientific Novel Søren Brier
    Ficta: remixing generalized symbolic media in the new scientific novel Søren Brier To cite this version: Søren Brier. Ficta: remixing generalized symbolic media in the new scientific novel. Public Un- derstanding of Science, SAGE Publications, 2006, 15 (2), pp.153-174. 10.1177/0963662506059441. hal-00571086 HAL Id: hal-00571086 https://hal.archives-ouvertes.fr/hal-00571086 Submitted on 1 Mar 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. SAGE PUBLICATIONS (www.sagepublications.com) PUBLIC UNDERSTANDING OF SCIENCE Public Understand. Sci. 15 (2006) 153–174 Ficta: remixing generalized symbolic media in the new scientific novel1 Søren Brier This article analyzes the use of fictionalization in popular science commu- nication as an answer to changing demands for science communication in the mass media. It concludes that a new genre—Ficta—arose especially with the work of Michael Crichton. The Ficta novel is a fiction novel based on a real scientific problem, often one that can have or already does have serious consequences for our culture or civilization. The Ficta novel is a new way for the entertainment society to reflect on scientific theories, their consequences and meaning.
    [Show full text]
  • Rhode Island Chapter Abstracts
    Rhode Island Chapter Abstracts April 1, 2015 Abdin, Ahmad Last Name: Abdin First Author: Resident First Name: Ahmad Category: Clinical Vignette PG Year: PGY-1 or MS Year: ACP Number: 2888549 Medical School or Residency Program: Warren Alpert Medical School of Brown University Hospital Affiliation: Memorial Hospital of Rhode Island, Providence VA Medical Center Additional Authors: Ahmad Abdin, MD, Mohammed Salhab, MD, Amos Charles, MD, Mazen Al-Qadi, MD Abstract Title: Amiodarone-Induced Cerebellar Dysfunction Abstract Text: Introduction: Amiodarone is a class III antiarrhythmic agent that is widely used to treat ventricular and supraventricular tachycardias. Several side-effects of the drug have been recognized including thyroid dysfunction, photosensitivity, hepatotoxicity, parenchymal lung disease, corneal deposits, and peripheral neuropathy. Cerebellar dysfunction is rarely seen in patients receiving amiodarone. We are reporting a rare case of amiodarone-induced cerebellar dysfunction that resolved completely upon discontinuation of the drug. Case Presentation: A 73-year-old man with a past medical history significant for paroxysmal atrial fibrillation, coronary artery disease, diabetes and hypertension who presented with worsening lower extremity weakness and unsteady gait with recurrent falls for the last 6 months. Two days prior to admission, his symptoms got worse and caused him to seek medical attention. Two years ago he was started and maintained on amiodarone 200 mg daily for rhythm control. On physical examination, vital signs were normal. A wide-based unsteady gait was noted. He had dysmetria bilaterally on finger-to-nose and heel-to-shin testing. The rapid alternating movements of the hands were irregular. The remainder of the general and neurologic examinations were unremarkable.
    [Show full text]
  • Nutrition Journal of Parenteral and Enteral
    Journal of Parenteral and Enteral Nutrition http://pen.sagepub.com/ Micronutrient Supplementation in Adult Nutrition Therapy: Practical Considerations Krishnan Sriram and Vassyl A. Lonchyna JPEN J Parenter Enteral Nutr 2009 33: 548 originally published online 19 May 2009 DOI: 10.1177/0148607108328470 The online version of this article can be found at: http://pen.sagepub.com/content/33/5/548 Published by: http://www.sagepublications.com On behalf of: The American Society for Parenteral & Enteral Nutrition Additional services and information for Journal of Parenteral and Enteral Nutrition can be found at: Email Alerts: http://pen.sagepub.com/cgi/alerts Subscriptions: http://pen.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav >> Version of Record - Aug 27, 2009 OnlineFirst Version of Record - May 19, 2009 What is This? Downloaded from pen.sagepub.com by Karrie Derenski on April 1, 2013 Review Journal of Parenteral and Enteral Nutrition Volume 33 Number 5 September/October 2009 548-562 Micronutrient Supplementation in © 2009 American Society for Parenteral and Enteral Nutrition 10.1177/0148607108328470 Adult Nutrition Therapy: http://jpen.sagepub.com hosted at Practical Considerations http://online.sagepub.com Krishnan Sriram, MD, FRCS(C) FACS1; and Vassyl A. Lonchyna, MD, FACS2 Financial disclosure: none declared. Preexisting micronutrient (vitamins and trace elements) defi- for selenium (Se) and zinc (Zn). In practice, a multivitamin ciencies are often present in hospitalized patients. Deficiencies preparation and a multiple trace element admixture (containing occur due to inadequate or inappropriate administration, Zn, Se, copper, chromium, and manganese) are added to par- increased or altered requirements, and increased losses, affect- enteral nutrition formulations.
    [Show full text]